JPH0562952B2 - - Google Patents
Info
- Publication number
- JPH0562952B2 JPH0562952B2 JP8753487A JP8753487A JPH0562952B2 JP H0562952 B2 JPH0562952 B2 JP H0562952B2 JP 8753487 A JP8753487 A JP 8753487A JP 8753487 A JP8753487 A JP 8753487A JP H0562952 B2 JPH0562952 B2 JP H0562952B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- lymphocytes
- cells
- lymphocyte
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004698 lymphocyte Anatomy 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 40
- 230000000638 stimulation Effects 0.000 claims description 27
- 210000003855 cell nucleus Anatomy 0.000 claims description 16
- 238000000684 flow cytometry Methods 0.000 claims description 16
- 230000022131 cell cycle Effects 0.000 claims description 15
- 230000035584 blastogenesis Effects 0.000 claims description 12
- 239000003226 mitogen Substances 0.000 claims description 12
- 239000007850 fluorescent dye Substances 0.000 claims description 10
- 230000006820 DNA synthesis Effects 0.000 claims description 9
- 210000000170 cell membrane Anatomy 0.000 claims description 9
- 230000004660 morphological change Effects 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 230000003716 rejuvenation Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 230000001885 phytohemagglutinin Effects 0.000 claims description 3
- 238000010998 test method Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 108010062580 Concanavalin A Proteins 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 235000015277 pork Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 24
- 230000035755 proliferation Effects 0.000 description 20
- 239000000523 sample Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 10
- 239000013068 control sample Substances 0.000 description 8
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 8
- 229960005542 ethidium bromide Drugs 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000003822 cell turnover Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000018199 S phase Effects 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000003154 fluorescent dye transfer Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000008216 juvenile development Effects 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8753487A JPS63252251A (ja) | 1987-04-09 | 1987-04-09 | フロ−サイトメトリ−によるリンパ球の幼若化試験法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8753487A JPS63252251A (ja) | 1987-04-09 | 1987-04-09 | フロ−サイトメトリ−によるリンパ球の幼若化試験法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63252251A JPS63252251A (ja) | 1988-10-19 |
| JPH0562952B2 true JPH0562952B2 (enExample) | 1993-09-09 |
Family
ID=13917653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8753487A Granted JPS63252251A (ja) | 1987-04-09 | 1987-04-09 | フロ−サイトメトリ−によるリンパ球の幼若化試験法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63252251A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023053574A1 (ja) * | 2021-09-29 | 2023-04-06 | 日東紡績株式会社 | 細胞または細胞核の豊富化方法 |
-
1987
- 1987-04-09 JP JP8753487A patent/JPS63252251A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63252251A (ja) | 1988-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blaxhall et al. | Routine haematological methods for use with fish blood | |
| US3916197A (en) | Method and apparatus for classifying biological cells | |
| JP2711786B2 (ja) | 試薬組成物とその細胞球形化への使用 | |
| FR2467402A1 (fr) | Methode d'essai biologique | |
| KR101847225B1 (ko) | 혈액 샘플 분석 방법 및 분석 시스템 | |
| US5830679A (en) | Diagnostic blood test to identify infants at risk for sepsis | |
| JPH06507969A (ja) | 蛍光団補助型炭水化物電気永動診断 | |
| SE442347B (sv) | Komposition for provning av biologiska vevnader eller vetskor innehallande ett dna-interaktivt fergemne och ett avexciterande emne, samt ett sett att anvenda kompositionen | |
| Kuethe et al. | Assessing the immune status of critically ill trauma patients by flow cytometry | |
| Rosenberg et al. | Diagnostic performance of inflammatory markers in gopher tortoises (Gopherus polyphemus) | |
| FI92076B (fi) | Lymfosyyttien tunnusmerkillinen potentiaalille herkkien aineiden sitominen | |
| JPH0562952B2 (enExample) | ||
| Tahari | Fluorescence correlation spectroscopy: Ultrasensitive detection in clear and turbid media | |
| JP2553606B2 (ja) | 密度特異血球の分離及び使用方法 | |
| DE69227623T2 (de) | Verfahren zum Nachweis einer CMV-Infektion | |
| Jarujareet et al. | Classification of beta-thalassemia major and HbE/beta-thalassemia via deep learning of image structure function image | |
| US3476514A (en) | Cancer cytoscreening | |
| Watson et al. | The incidence of Australia antigen and antibody in male prisoners of two Sydney penitentiaries | |
| RU94030511A (ru) | Способ диагностики состояния желудочно-кишечного тракта больного | |
| JP2955003B2 (ja) | 感作白血球の検出方法 | |
| IL46963A (en) | Reagent for detection of syphilis | |
| JP2001050953A (ja) | 白血球活性酸素産生量及び酸化ストレスの測定方法 | |
| Bietz | Development of a Synthetic Biomarker System for Early Detection of Myocardial Infarction | |
| SU1483374A1 (ru) | Способ определени степени т жести кандидоза | |
| DE19950262C2 (de) | Verfahren zur Durchführung eines durchflusszytometrischen Phagozytosetests |